Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study

Kral, Sabrina; Banfi, Chiara; Niedrist, Tobias; Sareban, Nazanin; Godballe, Christian; Kriegl, Lisa; Schiffmann, Stefanie; Zurl, Christoph; Herrmann, Markus; Steinmetz, Ivo; Schlenke, Peter; Berghold, Andrea; Krause, Robert

doi:10.1016/j.jinf.2021.08.030

Cited by 5 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 69 convalescent-phase sera used in this study (Convalescent Cohort [5003_20]) were obtained from nonhospitalized volunteers (median age = 42 years; range: 21–80) with confirmed COVID-19 infections between March 2020 and January 2021 ( 11 , 33 ). For cross-neutralization against the Alpha and Beta variants, we exclusively used sera before the emergence of the Alpha and Beta variants in Austria (COVID-19 diagnosis before November 2020).…”

Section: Methodsmentioning

confidence: 99%

“…For cross-neutralization against the Alpha and Beta variants, we exclusively used sera before the emergence of the Alpha and Beta variants in Austria (COVID-19 diagnosis before November 2020). The cohort’s characteristics were published previously by Kral et al ( 33 ). Serum collection and experiments were conducted under protocols reviewed and approved by the Ethical Review Committee of the Medical University of Graz (33-195 ex 20/21).…”

Section: Methodsmentioning

confidence: 99%

“…Sixty-nine convalescent-phase sera from the COVID-19 convalescent cohort (5003_20) were analyzed by the SARS-CoV-2-NeutraLISA (Euroimmun AG, Lübeck, Germany) to quantify immunoglobulin (Ig), which blocks RBD:angiotensin-converting enzyme-2 interaction. Total anti-RBD Ig of the same sera was previously quantified by the Elecsys Anti-SARS-CoV-2S ELISA (Roche Diagnostics GmbH, Mannheim, Germany) during a study, which monitored the immune response of 326 COVID-19 recovered individuals ( 33 ). Published Elecsys Anti-SARS-CoV-2S ELISA antibody concentration values of the 69 sera ( 33 ) were correlated with neutralization titers of our novel neutralization assay obtained in this study.…”

Section: Methodsmentioning

confidence: 99%

“…Total anti-RBD Ig of the same sera was previously quantified by the Elecsys Anti-SARS-CoV-2S ELISA (Roche Diagnostics GmbH, Mannheim, Germany) during a study, which monitored the immune response of 326 COVID-19 recovered individuals ( 33 ). Published Elecsys Anti-SARS-CoV-2S ELISA antibody concentration values of the 69 sera ( 33 ) were correlated with neutralization titers of our novel neutralization assay obtained in this study.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…This cohort's characteristics were published elsewhere. 5 Participants were observed for up to 12 months after inclusion. The date of the first positive SARS-CoV-2 PCR test was recorded as an estimate for the presumed time of infection.…”

Section: Study Population and Samplesmentioning

confidence: 99%

Longitudinal Comparison of Automated SARS-CoV-2 Serology Assays in Assessing Virus Neutralization Capacity in COVID-19 Convalescent Sera

Niedrist

Drexler

Torreiter

et al. 2022

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Context.– Serological tests on automated immunology analyzers are increasingly used to monitor the acquired immunity against SARS-CoV-2. The heterogeneity of assays raises concerns about their diagnostic performance and comparability. Objective.– To test sera from formerly infected individuals for SARS-Cov-2 antibodies utilizing six automated serology assays and a pseudoneutralization test (PNT). Design.– Six SARS-CoV-2 serology assays were utilized to assess 954 samples collected during a 12 months period from 315 COVID-19 convalescents. The tests determined either antibodies against the viral nucleocapsid (anti-NC) or spike protein (anti-S). Two assays did not distinguish between antibody classes whereas the others selectively measured immunoglubulins G (IgG) antibodies. PNT was used to detect the presence of neutralizing antibodies. Results.– Comparison of qualitative results showed only slight to moderate concordance between the assays (Cohen's kappa < 0.57). Significant correlations (P < .001) were observed between the antibody titers from all quantitative assays. However, titer changes were not detected equally. A total anti-S assay measured an increase in 128 out of 172 cases (74%) of a suitable subset, whereas all IgG anti-S tests reported decreases in at least 118 (69%). Regarding the PNT results, diagnostic sensitivities ≥89% were achieved with PPVs ≥93%. In contrast, specificity changed substantially over time varying from 20 to 100%. Conclusions.– Comparability of serological SARS-CoV-2 antibody tests is rather poor. Due to different diagnostic specificities, the tested assays were not equally capable of capturing changes in antibody titers. However, with thoroughly validated cut-offs, IgG-selective anti-S assays are a reliable surrogate test for SARS-CoV-2 neutralizing antibodies in former COVID-19 patients.

show abstract

Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection

Elslande¹,

Oyaert²,

Lorent³

et al. 2022

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS-CoV-2 infected patients from 2 university hospitals up to 365 days post positive RT-PCR. IgG anti-S and anti-N antibody levels decayed exponentially up to 365 days after a peak 0-59 days after positive RT-PCR. Peak antibody level/cut-off ratio 0-59 days after positive RT-PCR was more than 70 for anti-S compared to less than 6 for anti-N (p<0.01). Anti-S and anti-N were significantly higher in severe compared to non-severe patients up to 180-239 days and 300-365 days, respectively (p<0.05). Despite similar half-lives, the estimated time to 50% seronegativity was more than 2 years for anti-S compared to less than 1 year for anti-N in non-severe and severe COVID-19 patients, due to the significantly higher peak antibody level/cut-off ratio for anti-S compared to anti-N.

show abstract

Long-lasting immune response to a mild course of PCR-confirmed SARS-CoV-2 infection: A cohort study

Cited by 5 publications

References 10 publications

Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout

Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout

Longitudinal Comparison of Automated SARS-CoV-2 Serology Assays in Assessing Virus Neutralization Capacity in COVID-19 Convalescent Sera

Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection

Contact Info

Product

Resources

About